It’s good news for Allergan and Molecular Partners’ wet AMD drug. The duo announced Thursday that abicipar has met its endpoints in two Phase III trials, proving non-inferiority to the market-leading Lucentis.

In both 8- and 12-week regimens, abicipar met its primary endpoints, but also showed the incidence of intraocular inflammation was higher in patients on abicipar than those on Lucentis.

David Nicholson, Allergan

“We believe the SEQUOIA and CEDAR studies demonstrated what we set out to achieve, strong efficacy and duration of effect which shows the potential of abicipar as a treatment for AMD patients,” said David Nicholson, chief research and development officer at Allergan. “We have generated important findings in these trials to address a serious unmet need. We will continue to review these data including inflammation findings and are working on further optimizing the abicipar formulation.”

The filing for abicipar is planned for the first half of 2019, the company said. Allergan will be requesting a meeting with the FDA to discuss its BLA submission. The full data details of the primary and secondary endpoints will be presented at an upcoming scientific conference.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 31,500+ biopharma executives who read Endpoints News every day.